Journal Article |
| Tewari KS, Filiaci VL, Spirtos NM, Mannel RS, Thigen JT, Cibull ML, Monk BJ and Randall ME Association Of Number Of Positive Nodes And Cervical Stroma Invation With Outcome Of Advanced Endometrial Cancer Treated With Chemotherapy Or Whole Abdominal Irradiation: A Gynecologic Oncology Group Study. Gynecol Oncol. 125: 87-93, 2012 | 2011 |
| Rustin GJ, Vergote I, EIsenhauer E, Pujade-Lauraine NE, Quinn M, Thigpen T, deBois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Prmar M, Friedlaqnder M, Cervantes A and Vermorken J Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA-125 Agreed by the Gynecological Cancer Intergroup (GCIG) Int J Gynecol Cancer 21: 419-23 | 2011 |
| Stehman FB, Brady MF, Thigpen JT, Rossi EC and Burger R Impact of Cytokine Use on Survival in the First-Line Treatment of Ovarian Cancer: a Cynecologic Oncology Group Study In press in Gynecol Oncol | 2011 |
| Phuong M, Sherman ME, Piedmonte M, Ioffe OB, Ronnett BM, Van Le L, Mutch DG, Cohn DE, Thigpen JT, Tewari KS, DiSilvestro P, Kauff ND, Lu KU, Greene MH Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy among Wemen at Increased Ovarian Cancer Risk: Results from GOG-199 In press in Proc ASCO | 2011 |
| Farley J, Sill MW, birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG and Lankes HA Phase II Study of Cisplatin and Cetuximab in Advanced , Recurrent, and Previouly Treated Cancers of the Cervix and Evaluation of Epidermal Growth Receptor Immunohistochemical Expression: A Gynecologic Oncology Group Study Cynecol Oncol 121: 303-8 | 2011 |
| Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Thigpen JT, Fleming GF, Gallion HH, and Maxwell GL Chemotherapy Intensity and Toxicity among Black and White Women with Advanced or Recurrent Endometrial Cancer: Experience from Gynecologic Oncology Group Clinical Trials Cancer 116: 355-61, 2010 | 2010 |
| Moore KN, Tian C, McMeekin DS, Thigpen JT, Randall ME, and Gallion HH Does the Progression-Free Interval Following Primary Chemotherapy Predict Survival Following Salvage Chemotherapy in Advanced and Recurrent Endometrial Cancer? A Gynecologic Oncology Group Ancillary Data Analysis Cancer 116: 5407-14, 2010 | 2010 |
| Fleming GF, Sill M, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, and Fiorica JV Phase II Trial of Trastuzumab in Women with Advanced or Recurrent, HER2-Positive Endometrial Carcinoma: a Gynecologic Oncology Group Study Gynecol Oncol 116: 15-20, 2010 | 2010 |
| Sumrall A, Puneky L, Brown A, and Thigpen JT Ovarian Cancer in a Man Clin Ovarian Cancer C 2: 57-59, 2009 | 2009 |
| Trimble EL, Davis J, DiSaia P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J, Quinn M, Reed N, Schoenfeldt M, Thigpen, JT Clinical trials in gynecological cancer Int J Gynecol Cancer. 2007; 17: 547-56 | 2007 |
| Modesitt S, Tian C, Kryscio R, Thigpen T, Randall M, Gallion H, and Fleming G Impact of Body Mass Index on Treatment Outcomes in Advanced or Recurrent Endometrial Cancer Patients Receiving Doxorubicin/Cisplatin Chemotherapy: a Gynecologic Oncology Group Study Gynecologic Oncology 105: 59-65, 2007 | 2007 |
| Modesitt SC, Tian C, Kryscio R, Thigpen JT, Randall ME, Gallion HH, Fleming GF Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study Gynecol Oncol. 2007; 105: 59-65 | 2007 |
| Rose P, Ali S, Watkins E, Thigpen T, Deppe G, Clarke-Pearson D, and Insalaco S Long-Term Follow-up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin or Cisplatin-Based Combination Chemotherapy or Hydoxyurea during Pelvic Radiation Therapy for Locally Advanced Cervical Cancer J Clin Oncol 25: 2804-10, 2007 | 2007 |
| McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, and Rodgers WH The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study Gynecol Oncol 106: 16-22, 2007 | 2007 |
| McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007; 106:16-22 | 2007 |
| Randall ME, Brunetto VL, Muss H, Spirtos N, Mannel RS, Fowler J, Thigpen JT and Benda JA A Randomized Phase III Trial of Whole Abdominal Irradiation versus Combination Doxorubicin-Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 24: 1-10, 2006 | 2006 |
| Maxwell L, Tian C, Risinger J, Brown C, Thigpen T, Fleming G, Gallion H, and Brewster W Racial Disparity in Survival among Patients with Advanced/ Recurrent Endometrial Adenocarcinoma: a Gynecologic Oncology Group Study Cancer 107: 2197-2205, 2006 | 2006 |
| Thigpen, J.T., Blessing, J.A., DeGeest, K., Look, K.Y., Homesley, H.D Cisplatin as Initial Chemotherapy in Ovarian Carcinosarcomas: a Gynecologic Oncology Group Study Gynec Oncol 93: 336-339, 2004 | 2004 |
| Bigler, L., Thigpen, T., Blessing, J., Fiorica, J., Monk, B Evaluation of Tamoxifen in Persistent or Recurrent Non-Squamous Cell Carcinoma of the Cervix: a Gynecologic Oncology Group Study Intl J Gynec Cancer 14: 871-4, 2004 | 2004 |
| Poole GV, Thigpen T, Vance R and Barber WH Management of Women Who Present with T4 Breast Cancer Amer Surg 70: 662-666, 2004 | 2004 |
| Thigpen, J.T., Brady, M.F., Homesley, H.D., Malfetano, J., DuBeshte, B., Burger, R.A., Liao, S Phase III Trial of Doxorubicin with or without Cisplatin in Advanced Endometrial Carcinoma: a Gynecologic Oncology Study J Clin Oncol 22: 3902-3908, 2004 | 2004 |
| Thigpen, T., Blessing, J., Olt, G., Lentz, S., Bell, J Cisplatin as Salvage Therapy in Ovarian Carcinoma Treated Initially with Single-Agent Paclitaxel: a Gynecologic Oncology Group Study Gynec Oncol 90: 581-6, 2003 | 2003 |
| Streckfus C., Bigler L., Dellinger T., Dai X., Cox J., McArthur A., Kingman A., Thigpen T Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men Oral Surg Oral Med Oral Pathol Ofral Radiol Endod 91: 174-179, 2001 | 2001 |
| Thigpen T., Brady M., Homesley H., Soper J., Bell J Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 19: 364-367, 2001 | 2001 |
| Streckfus C., Bigler L., Tucci M., Thigpen T A preliminary study of CA 15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma Cancer Investigations 18: 101-109, 2000 | 2000 |
| Streckfus C., Bigler L., Dellinger T., Dai X., Kingman A., Thigpen T The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study Clinical Cancer Research 6: 2365-2370, 2000 | 2000 |
| Hensley, M., Schuchter, L., Lindley, C., Meropol, N., Cohen, G., Broder, G., Gradishar, W., Green, D., Langdon, R. Jr., Mitchell, R., Negrin, R., Szatrowski, T., Thigpen, T., Von Hoff, D., Wasserman, T., Winer, E., Pfister, D American Society of Clinical Oncology Clinical Practice Guidelines for the use of Chemotherapy and Radiotherapy Protectants J. Clin. Oncol. 17: 3333-3355, 1999 | 1999 |
| Patel M., Thigpen T., Vance R., Elkins S., Guo M Basal cell carcinoma with lung metastases diagnosed by fine-needle aspiration biopsy Southern Med J 92: 321-4, 1999 | 1999 |
| Streckfus C., Bigler L., Dellinger T., Pfeifer M., Rose A., Thigpen T CA 15-3 and c-erbB-2 presence in the saliva of women Clin Oral Invest 3: 138-143, 1999 | 1999 |
| Rose P., Bundy B., Watkins E., Thigpen T., Deppe G., Maiman M.. Clarke-Pearson D., d Insalaco S Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer New Eng J Med 340: 1144-1153, 1999 | 1999 |
| Thigpen, T., Brady, M., Alvarez, R., Adelson, M., Homesby, H., Monelta, A., Soper, J. and Given, F Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group J. Clin. Oncol. 17: 1736-1744, 1999 | 1999 |
| Thigpen T., Blessing J., Ball H., Hummel S., Barrett R Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study Classic Papers and Current Comments 3: 158-164, 1998 | 1998 |
| Harrison, T., Brigler, L., Tucci, M., Prett, L., MalaMud, F., Thigpen, T. and Streckfus, C Salivary SIGA Concentrations and Stimulated Whole Saliva Flow Rates Among Women undergoing Chemotherapy for Breast Cancer: an Exploratory Study Special Care in Dentistry 18:109-112, 1998 | 1998 |
| Thigpen, T., Blessing, J., Yordan, E., Valea, F., and Vaccarelleo, L Phase II Trial of Etoposide in Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study Gynecologic Oncology 63: 120-122, 1996 | 1996 |
| Thigpen, T., Blessing, J., Gallery, D., Mariman, M., and Soper, J Phase II Trial of Mitomycin C in Squamous Cell Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study Gynecol Oncol 57: 376-379, 1995 | 1995 |
| Thigpen, J. T., Blessing, J. A., Ball, H., Hummel, S., and Barrett, R. J A Phase II Trial of Taxol in Patients with Ovarian Carcinoma Progression after Prior Chemotherapy: A Gynecologic Oncology Group Study Journal Clinical Oncology 12:1748-1753, 1994 | 1994 |
| Thigpen, J. T., Blessing, J. A., DiSaia, P. J., Jordan, E., Carson, L. F., and Eers, C A Randomized Comparison of Doxorubicin Alone versus Doxorubicin plus Cyclophosphamide in the Management of Advanced or Recurrent Endometrial Carcinoma Journal of Clinical Oncology, 12:1408 - 1414, 1994 | 1994 |
| Thigpen, T., Brady, M. Omura, G. A., Creasman, W. T., McGuire, W. P., Hoskins, W. J., and Williams S Age as a Prognostic Factor in Ovarian Carcinoma Cancer 71: 606-614, 1993 | 1993 |
| Hoskins, W. J., Bundy, B. N., Thigpen, J. T., and Omura G. A The Influence of Cytoreductive Surgery on Recurrence-Free Interval and Survival in Small Volume Stage III epithelial Ovarian Cancer: A Gynecologic Oncology Group Study Gynecologic Oncology 47:159-166, 1992 | 1992 |
| Thigpen, J. T., Blessing, J. A., Beecham, J., Homesley, H. and Yordan, E Phase II Trial of Cisplatin as First-Line Chemotherapy in Patients with Advanced or Recurrent Uterine Sarcoma Clinical Oncology 9:1962-1966, 1991 | 1991 |
| Weiss, G., Green, S., Alberts, D. S., Thigpen, J. T., Hines, H. E., Hansen, K., Price, H. I., Bakers, L. H., and Godwin, J. W Second-Line Treatment of Advanced Measurable Ovarian Cancer with Iproplatin: A Southwest Oncology Group Study Eur. J. Cancer. 27:135-138, 1991 | 1991 |
| Morrow, C., Bundy, B., Homesley, H., Creasman, W., Hornback, N., Kurman, R., Thigpen, J Doxorubicin as an Adjuvant Following Surgery and Radiation Therapy in Patients with High-Risk Endometrial Carcinoma, Stage I and Occult Stage II: A Gynecologic Oncology Group Study Gynecology Oncology, 36:166-171, 1990 | 1990 |
| Thigpen, T., Blessing, J., DiSaia P., Fowler, W. Jr., Hatch K A Randomized Comparison of a Rapid Versus Prolonged (24 hr) Infusion of Cisplatin in Therapy of Squamous Cell Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study Gynecology Oncology, 32:198-202, 1989 | 1989 |
| Weiser, E. B., Bundy, B. N., Hoskins, W. J., Heller, P. B., Whittington, R. R., DiSaia, P. J., Curry, S. L., Schlaerth, J., and Thigpen, J. T Extra peritoneal versus Transperitoneal Selective Para-aortic Lymphadenectomy in the Pre-Treatment Surgical Staging of Advanced Cervical Carcinoma: A Gynecologic Oncology Group Study Gynecologic Oncology, 33:283-289, 1989 | 1989 |
| Thigpen, T., Blessing, J., Homesley, H., Creasman, W., and Sutton, G Phase II Trial of Cisplatin as First-Line Chemotherapy in Patients with Advanced or Recurrent Endometrial Carcinoma Gynecologic Oncology, 33:68-70, 1989 | 1989 |
| Thigpen, T., Blessing, J., Ball, H., Hanjani. P., Manetta, A., and Homesley, H Hexamethylmelamine as First-Line Chemotherapy in the Treatment of Advanced or Recurrent Carcinoma of the Endometrium Gynecologic Oncology, 31:435-438, 1988 | 1988 |
| Khansur, T., Balducci, L., Patel, B., and Thigpen, T Liver Scan and Carcinoembryonic Antigen in Staging and Follow-Up of Breast Cancer Breast Diseases, vol. 1, pp. 187-191, 1988 | 1988 |
| Khansur, T., Haick, A., Patel, B., Balducci, L., Vance, R., and Thigpen, T Preoperative Evaluation with Radio nuclide Brain Scan and Computed Tomography of Brain in Breast Cancer Ameri. J. Sur., vol. 155, pp. 232-233, 1988 | 1988 |
| Thigpen, T Continuous Infusion Velban in Advanced Endometrial Carcinoma American Journal of Clinical Oncology, 10:429-431, 1987 | 1987 |
| Khansur, T., Haick, A., Patel, B., Balducci, L., Vance, R., and Thigpen, T Evaluation of Bone Scan as a Screening Work up in Primary and Loco-regional Recurrences of Breast Cancer American Journal of Clinical Oncology, 10:167-170, 1987 | 1987 |
| Thigpen, J. T., Blessing, J. A., Orr, Jr., J. W., and DiSaia, P. J A Phase II Trial of Cisplatin in the Treatment of Patients with Advanced or Recurrent Mixed Mesodermal Sarcomas of the Uterus: A Gynecologic Oncology Group Study Cancer Treatment Reports 70:271-274, 1986 | 1986 |
| Thigpen, J. T., Blessing, J. A., and Wilbanks, G Cisplatin as Second-Line Chemotherapy in the Treatment of Advanced or Recurrent Leiomyosarcoma of the Uterus: A Phase II Trial of the Gynecologic Oncology Group American Journal of Clinical Oncology 9:18-20, 1986 | 1986 |
| Thigpen, J., Blessing, J. A., Homesley, H., and Creasman, W. T Phase II Trial of Cisplatin in Advanced or Recurrent Cancer of the Vagina: A Gynecologic Oncology Group Study Gynecologic Oncology 23:101-104, 1986 | 1986 |
| Thigpen, J. T., Blessing, J. A., Homesley, H., and Petty, W Phase II Trial of Piperazinedione in Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study American Journal of Clinical Oncology 9:21-23, 1986 | 1986 |
| Thigpen, J. T., Blessing, J. A., Fowler, W. C., and Hatch, K Phase II Trials of Cisplatin and Piperazinedione as Single Agents in the Treatment of Advanced or Recurrent Non-Squamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study Cancer Treatment Reports 70:1097-1100, 1986 | 1986 |
| Thigpen, J. T., Blessing, J. A., Homesley, H., and Lewis, Jr., G. C Phase II Trials of Cisplatin and Piperazinedione in Advanced or Recurrent Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study Gynecologic Oncology 23:358-363, 1986 | 1986 |
| Balducci, L., Newcomb, M., Vance, R., and Thigpen, T L-Asparaginase-Methotrexate Combination in the Treatment of Non-Small Cell Lung Cancer J. Exp. Clin. Cancer Res. 4:21-23, 1985 | 1985 |
| Thigpen, J. T., Blessing, J. A., Homesley, H., Hacker, N. F., and Curry, S. L Phase II Trial of Piperazinedione in Patients with Advanced or Recurrent Uterine Sarcoma: A Gynecologic Oncology Group Study American Journal of Clinical Oncology 8:350-352, 1985 | 1985 |
| Jobson, V., Muss, H., Thigpen, T., Homesley, H., and Bundy, B Chemotherapy of Advanced Squamous Carcinoma of the Cervix: Phase I-II Study of High Dose Cisplatin and Cyclophosphamide American Journal of Clinical Oncology 7:345, 1984 | 1984 |
| Thigpen, T., Blessing, J., LaGasse, L., Di Saia, P., and Muss, H Phase II Trial of Cisplatin as Second-Line Chemotherapy in Patients with Advanced or Recurrent Endometrial Carcinoma American Journal of Clinical Oncology 7:253-256, 1984 | 1984 |
| Thigpen, T., Blessing, J., Arseneau, J., and Muss, H Phase II Trial of Piperazinedione in the Treatment of Advanced or Recurrent Carcinoma of the Ovary American Journal of Clinical Oncology 7:261-264, 1984 | 1984 |
| Omura, G., Major, F., Blessing, J., Lewis, G., and Thigpen, T A Randomized Study of Adriamycin with and without Dimethyl Triazinoimidazole Carboxamide in Advanced uterine Sarcomas Cancer 52:626-632, 1983 | 1983 |
| Thigpen, T., LaGasse, L., Homesley, H., and Blessing, J Cis-Platinum in the Treatment of Advanced or Recurrent Adenocarcinoma of the Ovary: A Phase II Study of the Gynecologic Oncology Group American Journal of Clinical Oncology 6:431-436, 1983 | 1983 |
Thigpen, T., Ehrlich C., Conroy J., Blessing J Phase II study of Maytansine in the
Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study American Journal of Clinical Oncology 6:427-430, 1983 | 1983 |
| Thigpen, T., and Ehrlich, C., Creasman, W., Cury, S., and Blessing, J Phase II Study of Maytansine in the Treatment of Advanced or Recurrent Adenocarcinoma of the Ovary: A Gynecologic Group Study American Journal of Clinical Oncology 6:273-276, 1983 | 1983 |
| Tranum, B., Samal, B., Thigpen, T., Vaughn, C., Wilson, H., Maloney, T., Costanzi, J., Bickers, J., Gad el Mawli, N., Palmer, R., Hoostraten, B., Heilbrun, L., and Rasmusen, S Adriamycin Combinations in Advanced Breast Cancer Cancer 49:835-839, 1982 | 1982 |
| Thigpen, T., Blessing, J., Vance, R., and Balducci, L Chemotherapy in the Management of Advanced or Recurrent Cervical and Endometrial Cancer Cancer 48:658-665, 1981 | 1981 |
| Thigpen, T., Shingleton, H., Homesley, H., LaGasse, L., and Blessing, J Cis-Platinum in Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group Cancer 48:899-903, 1981 | 1981 |
| Vaughn, C., Panettiere, F., Thigpen, T., Bottomley, R., Hoogstratten, B., and Baker, L Phase II Evaluation of 4-Dimethyl-E-pipodophyl-lotoxin-B-Dethylidone Glucoside (VP-16-213) NSC-14150 In Patients with Advanced Breast Cancer: A Southwest Oncology Group Study Cancer Treatment Reports 65:443-445, 1981 | 1981 |
| Haas, C. D., Baker, L., and Thigpen, T Phase II Evaluation of Dianhydrogalactitol in Lung Cancer: A Southwest Oncology Group Study Cancer Treatment Reports 65-115-118, 1981 | 1981 |
| Thigpen, T., Vaughn, c., and Stuckey, W. J Phase II Trial of Anguidine in Treatment of Advanced Soft-Tissue and Bony Sarcomas. A Southwest Oncology Group Study Cancer Treatment Reports 65:881-882, 1981 | 1981 |
| Thigpen, T., Shingleton, H., Homesley, H., LaGasse, L., and Blessing, J Cis-Platinum in the Management of Cervix and Uterine Cancer: Phase II Experience of the Gynecologic Oncology Group Cisplatinum: Current Status and New Developments. pp. 411-421, Academic press, 1980, New York | 1980 |
| Yap, B., Sinkovics, J., Baker, L., Rivkin, S., Bottomley, R., Thigpen, T., Burgess, A., Benjamin, R., and Bodey, G CYVADIC Combination Chemotherapy in the Treatment of Advanced Sarcomas Cancer Treatment Reports 64:93-98, 1980 | 1980 |
| Buroker, T., Kim, P. N., Groppe, C., McCracken, J., O’Bryan, R., Panatierre, F., Costanzi, J., Bottomley, R., King, G. W., Bonnet, J., Thigpen, T., Whitecar, J., Haas, C., Vaitkevicius, V. K., Hoostraten, B., and Heilbrun, L 5-FU Infusion with Mitomycin-C vs 5-FU Infusion with Methyl-CCNU in the Treatment of Advanced Upper Gastrointestinal Cancer Cancer 44:1215-1221, 1979 | 1979 |
| Sall, S., DiSaia, P., Thigpen, T., Morrow, C. P., Mortel, R., Prem, K., and Creasman, W A Comparison of Medroxyprogesterone Serum Concentration in Patients with Persistent or Recurrent Endometrial Carcinoma by the Oral or Intramuscular Rouge Amer. J. Obstetr. Gynecol. 135:647-650, 1979 | 1979 |
| Alberts, D., Moon, T., O’Toole, R., Neff, J., Thigpen, T., and Blessing, J BCG as an Adjuvant to Adriamycin-Cyclophosphamide in the Treatment of Advanced Ovarian Carcinoma Salmon, S., and Jones, S., eds. Adjuvant Therapy for Cancer. Alan R. Liss, pp. 483-494, 1979 | 1979 |
| Thigpen, T., Shingleton, H., Homesley, H., LaGasse, L., and Blessing, J Cis-Diamminedichloroplatinum (NSC-119875) in Treatment of Gynecologic Malignancies: Phase II Trials by the Gynecologic Oncology Group Cancer Treatment Reports 63:1549-1556, 1979 | 1979 |
| Rossof, A. H., Talley, R. W., Stephens, R. L., Thigpen, T., Vaitkevicius, V. K., Hewlett, J. S., Athens, J., and Fisher, R Phase II Evaluation of Cis-Diamminedichloroplatinum (II) in Advanced Malignancies of the Genitourinary and Gynecologic Organs Cancer Treatment Reports 63:1557-1564, 1979 | 1979 |
| Thigpen, T., Buchsbaum, H., Mangan, C., and Blessing, J Phase II Trial of Adriamycin in the Treatment of Advanced or Recurrent Endometrial Carcinoma Cancer Treatment Reports 63:21-28, 1979 | 1979 |
| Alberts, D., Moon, T., Stephens, R., Wilson, H., Oiski, N., Hilgers, R., O’Toole, R., and Thigpen, T Randomized Study of Chemoimmunotherapy for Advanced Ovarian Carcinoma: A Preliminary Report of a Southwest Oncology Group Study Cancer Treatment Reports 63:325-331, 1979 | 1979 |
| Buroker, T., Kim, P. N., Groppe, C., McCracker, J., O’Bryan, R., Panettier, F., Coltman, C., Bottomley, R., Wilson, H., Bonnett, J., Thigpen, T., Vaitkevicius, V. K., Hoostrate, B., and Heilbrun, L 5-FU Infusion with Mitomycin-C Versus 5-FU Infusion with Methyl-CCNU in the Treatment of Advanced Colon Cancer Cancer 42:1228-33, 1978 | 1978 |
| Newcomb, M., Balducci, L., Thigpen, T., and Morrison, F Acute Leukemia in Pregnancy: Successful Delivery after Cytarabine and Doxorubicin JAMA 239:2691-2692, 1978 | 1978 |
| Livingston, R. B., Heilbrum, L. H., Thigpen, T., Coltman, Jr., C. A., and Haus, C Adriamycin and Chlorambucil vs Adriamycin and Thiabendazole in the Treatment of Extensive Non-Small Cell Carcinoma of the Lung. A Southwest Oncology Group Pilot Study Cancer Treatment Reports 62:1215-1217, 1978 | 1978 |
| Tranum, B., Hoogstraten, B., Kennedy, A., Vaughn, C. B., Samal, B., Thigpen, T., Rivkin, S., Smith, F., Palmer, R. L., Costanzi, J., Tucker, W. G., Wilson, H., and Maloney, T. R Adriamycin in Combination for the Treatment of Breast Cancer Cancer 41:2078-2083, 1978 | 1978 |
| McKelvey, R. M., Hewlett, J. S., Thigpen, T., and Whitecar, J Cyclocytidine Chemotherapy in Malignant Melanoma Cancer Treatment Reports 62:469-471, 1978 | 1978 |
| Cecil, J. W., Quagliana, J. M., Tucker, W. G., Coltman, C. A., McDonald, B. M., Al-Sarraf, M., Thigpen, T., and Groppe, Jr., C. W Evaluation of VP-16213 in Malignant Lymphoma and Melanoma Cancer Treatment Reports 62:801-803, 1978 | 1978 |
| Thigpen, T., Al-Sarraf, M., and Hewlett, J. S Phase II Trial of Dianhydrogalactitol in Malignant Melanoma Cancer Treatment Reports 63:553-554, 1978 | 1978 |
| Al-Sarraf, M., Thigpen, T., Grope, C., Haut, A., and Padilla, F Piperazinedione (NSC-135758) in Previously Treated Patients with Advanced Malignant Melanoma: Phase II Trial Cancer Treatment Reports 62:1101-1103, 1978 | 1978 |
| Livingston, R. B., Moore, T. N., Heilbrum, L., Bottomley, R., Lehan, D., Rivkin, S. E., and Thigpen, T Small Cell Carcinoma of the Lung: Combined Chemotherapy and Radiation Ann. Int. Med. 88:194-199, 1978 | 1978 |
| Hoogstraten, B., George, S. L., Samal, B., Rivkin, S. E., Constanzi, J. J., Bonnet, J. D., Thigpen, T., and Braine, H Combination Chemotherapy and Adriamycin in Patients with Advanced Breast Cancer. A Southwest Oncology Group Study Cancer Treatment Reports 61:1485-1487, 1977 | 1977 |
| Thigpen, T., O’Bryan, R. M., Benjamin, R., and Coltman, Jr., C. A Phase II Trial of Baker’s Antifol (BAF, NSC, 139105) in Metastatic Sarcoma. A Southwest Oncology Group Study Cancer Treatment Reports 61:1485-1487, 1977 | 1977 |
| Benjamin, R. S., Baker, L. H., Rodriguez, V., Moon, T. E., O’Bryan, R. M., Stephens, R. L., Sinkovics, J. G., Thigpen, T., King, G. W., Bottomley, R., Groppe, Jr., C. W., Bodey, G. P., and Gottlieb, J. A The Chemotherapy of Soft-Tissue Sarcomas in Adults Management of Soft-tissue Tumors. PP. 309-317, Yearbook, 1977 | 1977 |
| Thigpen, J. T., Morrison, F. S., Smith, D. L., and Maiser, F. G Diagnostic Considerations in CNS Leukemia: A Case Report Southern Medical Journal 69:76-78, 1976 | 1976 |
| Gottlieb, J. A., Benjamin, R. S., Baken, L. H., O’Bryan, R. M., Sinkovics, J. G., Hoogstratn, R., Quagliana, J. M., Rivkin, S. E., Bodey, G. P., Rodriguez, V., Blumenschein, G. R., Saiki, J. H., Coltman, C., Burgess, M. A., Sullivan, P., Thigpen, T., Bottomly, R., Balcerzak, S., and Moon, T. E The Role of DTIC (Dimethyl Triazeno Imadizole Carboxamide, Decarbazine, NSC 45388) in the Chemotherapy of Sarcomas Cancer Treatment Reports 60:199-204, 1976 | 1976 |
| Gottlieb, J. A., Baker, L. H., O’Bryan, R. M., Sinkovics, J. G., Hoogstraten, R., Quagliana, J. M., Rivking, S. E., Bodey, Sr., G. P., Rodriquen, V. T., Blumenshein, F. R., Saiki, J. H., Coltman, Jr., C., Burgess, M. A., Sullivan, P., Thigpen, J. t., Bottomley, R., Balcerzak, S., Moon, T. E Adriamycin Used Alone and in Combination in Soft-tissue and Bony Sarcomas Cancer Chemotherapy Reports. Part 3, 6:2710-282, 1975 | 1975 |
| Holcomb, B. W., Thigpen, J. T., Puckett, J., and Morrison, F. S Generalized Melanosis Complicating Disseminated Malignant melanoma in Pregnancy: A Case Report Cancer 35-1459-1464, 1975 | 1975 |
| Thigpen, J. T., Steinberg, M. H., Beutler, E., Gillespie, G., Dreiling, B., and Morrison, F. S G-6PD Jackson: A New Variant Associated with Hemolytic Anemia Acta hematologica. 51:310-314, 1974 | 1974 |
| Steinber, M. H., Adams, J., Thigpen, J. T., Morrison, F. S., and Dreiling, B Hemoglobin Hope (2 B2 136 glyasp) - S Disease: Clinical and Biochemical Studies J. Lab Clin. Med. 84:632-642, 1974 | 1974 |
| Farley J, Sill MW, Birrer M, Walker J, Schilder R, Thigpen JT, Coleman RL, Miller BE, Rose PG, and Lankes HA Phase II Study of Cisplatin Plus Cetuximab in Advanced, Recurrent, and Previously Treated Cancers of the Cervix and Evaluation of Epidermal Growth Factor Receptor Immunohistochemical Expression: a Gynecologic oncology Group Study Gynecologic Oncology 121: 303-8, 2011 | |
| Long, B. W., Thigpen, J. T., and Morrison, F. S Paraneoplastic Manifestations in Gastric Carcinoma J. Miss. State Med. Assoc. 16:337-339, 1975 | 1975 |
Review Article |
| STuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T and Trimble E 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical GTrials in Overian Cancer: Report from the Fourth Ovarian Cancer Consensus Conference Int J Gynecol Cancer 21: 750-5 | 2011 |
| Thigpen T A Rational Approach to the Management of Recurrent or Persistent Ovarian Carcinoma Clin Obstet Gynecol. 55: 114-30, 2012 | 2011 |
| Rustin, G., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G., Jakobsen, A., Sagae, S., Greven, K., Parmar, M., Friedlander, M., Cervantes, A., Vermorken, J Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup International Journal of Gynecologic Cancer 21: 419-423, 2011 | 2011 |
| Thigpen JT Con: Patients with Metastatic/Recurrent Cervical Cancer Should Not Be Treated with Cisplatin Plus Paclitaxel Clinical Ovarian Cancer 3: 2010 | 2010 |
| Thigpen JT Con: Systemic Therapy for All Endometrial Carcinomas Should Not Be Paclitaxel Plus Carboplatin Clinical Ovarian Cancer 3: 2010 | 2010 |
| Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A, von Hoff D, and Schucter LM American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants J Clin Oncol 27: 127-45, 2009 | 2009 |
| Thigpen JT Debate: Secondary Surgical Debulking Is Not an Acceptable Option in Patients with Recurrent Platinum-Sensitive Ovarian Cancer Clin Ovarian Cancer 2: 21-23, 2009 | 2009 |
| Thigpen JT Debate: Patients with Any Stage I Ovarian Cancer Should Undergo Complete Surgical Resection Followed by Six Cycles of Adjuvant Carboplatin/Paclitaxel Clin Ovarian Cancer 1: 16-21, 2008 | 2008 |
| Thigpen JT Debate: Patients with Endometrial Carcinoma with Extrauterine Disease Should Receive Chemotherapy after Any Indicated Surgery Clin Ovarian Cancer 1: 104-6, 2008 | 2008 |
| Thigpen JT Debate: Therapy for a Patient with Platinum-Resistant/Refractory Recurrent Ovarian Cancer Should Be Selected Based on Results of an In Vitro Drug Sensitivity/Resistance Assay Clin Ovarian Cancer 1: 96-98, 2008 | 2008 |
| Armstrong D, Thigpen JT, and Wolf JK Management of Persistent, Recurrent, and Refractory Ovarian Cancer Medical Communications Media, 2008 | 2008 |
| Thigpen JT Treating Older Patients with Ovarian Cancer: Another Perspective Oncology 22: 1592-5, 2008 | 2008 |
| Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, and Pazdur R Clinical Trials Endpoints in Ovarian Cancer: Report of an FDA/ASCO/AACR Public Workshop Gynecol Oncol 107: 173-6, 2007 | 2007 |
| Trimble ET, Davis J, DiSaiaq P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J, Quinn M, Reed N, Schoenfeldt M, and Thigpen JT Clinical Trials in Gynecologic Cancer Intl J Gynec Cancer 17: 547-56, 2007 | 2007 |
| Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pears DL, Insalaco S; Gynecologic Oncology Group Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study J Clin Oncol. 2007; 25: 2804-10 | 2007 |
| Thigpen T The Role of Gemcitabine in First-Line Treatment of Advanced Ovarian Carcinoma Semin Oncol 33: S26-S32, 2006 | 2006 |
| Herzog TJ, Coleman RL, Markman M, Cella D, and Thigpen T The Role of Maintenance Therapy and Novel Taxanes in Ovarian Cancer Gynec Oncol 102: 218-25, 2006 | 2006 |
| du Bois A, Quinn M, Thigpen T, Vermorken J et al 2004 Consensus Statements on the Management of Ovarian Cancer: Final Document of the Third International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annals of Oncology 16: viii7-viii12, 2005 | 2005 |
| Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalia JP, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Poveda A, Provencher D, Stehman F and Vergote I Clinical Trials in Ovarian Carcinoma: Requirements for Standard Approaches and Regimens Annals of Oncology 16: viii13-viii19, 2005 | 2005 |
| Quinn M, Avall-Lundqvist E, du Bois A, Vermorken J, Parmar M, Pfisterer J, Stuart G, Thigpen T, and Neijt J History, Scope and Methodology of the Third International Consensus Workshop on Ovarian Cancer 2004 Annals of Oncology 16: viii5-viii6, 2005 | 2005 |
| Thigpen, J.T Innovations in Anthracycline Therapy: Overview Community Oncology 2: 3-7, 2005 | 2005 |
| Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ and Rose PG Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer Gynec Oncol 96: 10-18, 2005 | 2005 |
| Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlander M, Fujiwara K, Grenman S, Guastalla J, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, and Wagner U Third International Ovarian Cancer Consensus Conference: Outstanding Issues for Future Consideration Annals of Oncology 16: viii36-viii38, 2005 | 2005 |
| Thigpen T First-Line therapy for Ovarian Carcinoma: What’s Next Cancer Invest 22: 19-26, 2004 | 2004 |
| Chu C and Thigpen JT The Role of Chemotherapy in Gynecologic Cancer Rubin SC, ed, Chemotherapy of Gynecologic Cancers, Second Edition, 2004, pp101-126 | 2004 |
| Thigpen T The Role of Chemotherapy in the Management of Carcinoma of the Cervix Cancer J 9: 425-432, 2003 | 2003 |
| Thigpen T Review of Update on Radiation Therapy for Endometrial Cancer Oncology 16: 791, 2002 | 2002 |
| Thigpen, T The Role of Gemcitabine-Based Doublets in the Management of Ovarian Carcinoma Semin Oncol 29 (1 Suppl 1): 11-16, 2002 | 2002 |
| Thigpen, T Gynecologic Cancer Current Oncology Reports 3: 11-40, 2001 | 2001 |
| Thigpen T Chemotherapy for advanced ovarian cancer: overview of randomized trials Semin Oncol 27 (suppl 7): 11-16, 2000 | 2000 |
| Patel, M., Bigler, S., Streckfus, C., Elkins, S., Thigpen, T., Vance, R. and Bigler, L Limited Expression of C-erbB-2 in Node-Negative Breast Cancer Patients J Miss Acad Sci 45: 215-218, 2000 | 2000 |
| Herrin V., Thigpen T Recent developments in the treatment of recurrent ovarian carcinoma Advances in Oncology 16: 21-29, 2000 | 2000 |
| Berek J., Bertelsen K., du Bois A., Brady M., Carmichael J., Eisenhauer E., Gore M., Grenman S., Hamilton T., Hansen S., Harper P., Horvath G., Kaye S., Luck H., Lund B., McGuire W.P., Neijt J., Ozols R., Parmar M., Piccart-Gebhart M., van Rijswijk, R., Rosenberg P., Rustin G., Sessa C., Thigpen T., Trope C., Tuxen M., Vergote J., Vermorken .J., Willemse P Advanced epithelial ovarian cancer: 1998 consensus statement Ann Oncol 10 (suppl 1): S87-S92, 1999 | 1999 |
| Herrin V., Thigpen T Chemotherapy for ovarian cancer: current concepts Semin Surg Oncol 17: 181-8, 1999 | 1999 |
| Du Bois A., Neijt J., Thigpen T First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care Ann Oncol 10 (suppl 1): S35-S41, 1999 | 1999 |
| Herrin V., Thigpen T High-dose chemotherapy in ovarian carcinoma Semin Oncol 26: 1-8, 1999 | 1999 |
| Thigpen T Limited-stage ovarian cancer Semin Oncol 26 (suppl 18): 29-33, 1999 | 1999 |
| Thigpen T Paclitaxel in celomic epithelial carcinoma of the ovary: the Gynecologic Oncology Group experience Aktuelle Onkologie 102: 1-18, 1999 | 1999 |
| Brady M., Thigpen T., Vermorken J., Parmar M Randomised trials in ovarian cancer: trial design considerations Ann Oncol 10 (suppl 1): S75-S82, 1999 | 1999 |
| Thigpen T Second-line therapy for ovarian carcinoma: general concepts Perry M, ed, American Society of Clinical Oncology 1999 Educational Book, ASCO, Alexandria, VA, 1999, pp. 564-566 | 1999 |
| Thigpen, T., Vance, R., Khansur, T., and Malamud F The Role of Chemotherapy in the Management of Celomic Epithelial Carcinoma of the Ovary Cancer Investigations, 15: 277-287, 1997 | 1997 |
| Thigpen, T Abnormal Radio labeled Antibody Scan in an Ovarian Cancer Patient: Physician’s Response Markman, M. and Belinson, J., eds., Expert Consultations in Gynecologic Cancers, Marcel Dekker, New York, 1996 | 1996 |
| Thigpen, T Advanced Borderline Tumor of the Ovary: Physician’s Response Markman, M. and Belinson, J., eds. Expert Consultations in Gynecological Cancers, Marcel Dekker, New York, 1996 | 1996 |
| Thigpen, T., Vance, R., Khansur, T., and Malamud, F Paclitaxel in Celomic Epithelial Carcinoma of the Ovary: A Review of the Gynecologic Oncology Group Experience Seeber, S., Meerpohl, H. G., Kuhnle, H., and Diergarten, K., eds, Taxol: Ergebnisse der Therapie beim Ovarcalkarzinom, Mammalkarzinom, nicht-Kleinzelligen Bronchiakarzinom, W., Zuckschwerdt Verlay, Munich, 1996, pp. 20-34 | 1996 |
| Thigpen, T Small Cell Carcinoma of the Cervix: Physician’s Response Markman, M., and Belinson, J., eds. Expert Consultations in Gynecological Cancers, Marcel Dekker, New York, 1996 | 1996 |
| Thigpen, T., Vance, R., Khansur, T., and Malamud, F The Management of Advanced Ovarian Carcinoma: Recent Results of U.S. Trials with Emphasis on Trials of the Gynecologic Oncology Group Aktuelle Onkologie 95: 61-71, 1996 | 1996 |
| Thigpen, T., Vance, R., Puneky, L. and Khansur, T Chemotherapy as a Palliative Treatment in Carcinoma of the Uterine Cervix Seminar Oncol 22 (Suppl. 3): 16-24, 1995 | 1995 |
| Thigpen, T Recent Progress and New Approaches in the Management of Celomic Epithelial Carcinoma of the Ovary Cancer Chemotherapy, 10th Nagoya International Symposium On Cancer Treatment, 1995, p. 39 | 1995 |
| Thigpen, T., Vance, R., and Khansur, T The Platinum Compounds and Paclitaxel in the Management of Carcinomas of the Endometrium and Uterine Cervix Semin. Oncol. 22 (Suppl. 12): 67-75, 1995 | 1995 |
| Thigpen, T., Vance, R., McGuire, W., Hoskins, W., Brady, W The Role of Paclitaxel in the Management of Celomic Epithelial Carcinoma of the Ovary: A Review with Emphasis on the Gynecologic Oncology Group Experience Semin. Oncol. 22 (Suppl. 14): 23-31, 1995 | 1995 |
| Thigpen, T Cancers of the Cervix and Endometrium Semin Oncol 21:1-123, 1994 | 1994 |
| Thigpen, T., Stehman, F. B. and Homesley H Cancers of the Uterine Cervix and Endometrium: Major Issues and Future Research Direction Semin Oncol 21:114-118, 1994 | 1994 |
| Thigpen, T., Vance, R. B., and Khansur, T Carcinoma of the Uterine Cervix: Current Status and Future Directions Seminars in Oncology, 21 (Suppl 2); 543-556, 1994 | 1994 |
Allen, D. G., Daak, J., Belpomme, D., Berch, J. S., Bertelsen, K., ten Bokkel Huinink, W. W., Van der Burg, Mel Calvert, A. W., Conte, P. F., Dauplat, J.,Eissenhauer, E.A.,
Favalli, G., Hactur, N. F., Hamilton, T. C., Hansen, H. H., Hansen, M., Van Houwelingen, H. C., Kaye, S. B., Levin, L., Lund, B., Neijt, J. P., Ozols, R. F., Piezan M. Z., Rustin, G. J. S., Sessa, C., Souter, W. P., Thigpen, J. T., Vermorken, J. B., and de Vries, E. G Advanced Epithelial Ovarian Cancer: 1993 Consensus Statements Annals of Oncology, 4 (Suppl 4): S83-S88, 1993 | 1993 |
| Park, R. C. and Thigpen, J. T Chemotherapy in Advanced and Recurrent Cervical Cancer: A Review Cancer. 71:1446-1450, 1993 | 1993 |
| Ozols, R. F., Thigpen, J. T., Dauplat, J., Colombo, N., Precart, M. J., Bertelsen, K., Levin L., and Lund, B Dose Intensity Annals of Oncology, 4 (Suppl 4): S49-S56, 1993 | 1993 |
| Thigpen, J. T., Bertelsen, K., Eisenhauer, E. A., Hacher, N. F., Luval, B., and Sessa C Long-Term Follow-Up of Patients with Advanced Ovarian Carcinoma Treated with Chemotherapy Annals of Oncology, 4 (Suppl 4): S35-S40, 1993 | 1993 |
| Hansen, H. H., Eisenhauer, E. A., Hansen, M., Neijt, J. P., Precart, M. J., Sessa, C., and Thigpen, J. T New Cytostatic Drugs in Ovarian Cancer Annals of Oncology 4 (Suppl. 4): 63-70, 1993 | 1993 |
| Thigpen, J. T., Vance, R. B., and Khansur, T Second-Line Chemotherapy for Recurrent Carcinoma of the Ovary Cancer. 71:1559-1564, February, 1993 | 1993 |
| Morgan, D. P., and Thigpen, J. T Chemotherapy in Gynecologic Cancer: Celomic Epithelium Carcinoma of the Ovary Clinical Consult. Obstet. Gynecol. 4:144-151, 1992 | 1992 |
| Thigpen, T., Lambuth, B. W., and Vance, R. B The Role of Ifosfamide in Gynecologic Cancer Seminars in Oncology, Vol. 19 (1), Suppl. 1, pp. 30-34, February, 1992 | 1992 |
| Park, R. C., and Thigpen, J. T Cancer of the Uterine Cervix: The Gynecologic Group Experience Postgrad Obstet. Gynecol. 11 (No. 16):1-5, 1991 | 1991 |
| Park, R. C., and Thigpen, J. T Cancers of the Uterine Corpus: The Gynecologic Oncology Group Experience Postgrad. Obstet. Gynecol. 11 (No. 17): 1-5, 1991 | 1991 |
| Thigpen, J. T., Lambuth, B. W., and Vance, R. B Management of Stage I and II Ovarian Carcinoma Seminars in Oncology, Vol. 18, No. 6, pp. 30-34, (December), 1991 | 1991 |
| Thigpen, T Carcinoma of the Ovary: An Overview of Standard Therapy Proceedings of New Survival Data in Ovarian Cancer, pp. 1-7, U.S. Biosciences, Conshokochen, PA, 1990 | 1990 |
| Thigpen, T., Blessing, J., Vance, R., and Lambuth, B Ifosfamide in the Management of Gynecologic Cancer Seminars in Oncology 17 (Supp. 4) 11-18, 1990 | 1990 |
| Thigpen, T., Blessing, J., Vance, R., and Lambuth, B Management of Patients with Stage I and II Ovarian Carcinoma Proc. Perugia International Cancer Conference II, pp. 41-49, LP Communications, New York, 1990 | 1990 |
| Thigpen, T., Blessing, J., Vance, R., and Lambuth, B Chemotherapy in Ovarian Carcinoma: Present Role and Future Prospects Seminars in Oncology, 16:58-65, 1989 | 1989 |
| Thigpen, J. T Chemotherapy of Gynecologic Tumors Cur. Opin. Oncol. 1:105-111, 1989 | 1989 |
| Thigpen, T., Vance, R., and Lambuth, B Diagnosis and Management of Ovarian Carcinoma Comprehensive Therapy, 14:29-35, 1988 | 1988 |
| Thigpen, T., Vance, R., and Lambuth, B Ovarian Carcinoma: The Role of Chemotherapy Seminars in Oncology 15 (Suppl.), 16-23, June, 1988 | 1988 |
| Thigpen, T., Vance, R., Lambuth, B., Balducci, L., Khansur, T., Blessing, J., and McGehee, R Chemotherapy for Advanced or Recurrent Gynecologic Cancer Cancer, 60:2104-2116, 1987 | 1987 |
| Thigpen, J. T., Morrow, C. P., and Blessing, J. A Adjuvant Chemotherapy in High-Risk Endometrial Carcinoma: The Gynecologic Oncology Group Experiences Bolla, M., et al, eds, Endometrial Cancer, Cancer Research Workshop, pp. 223-232, 1986, Karger, Basel | 1986 |
| Thigpen, J. T., Morrow, C. P., and Blessing, J. A Chemotherapy in Advanced or Recurrent Endometrial Carcinoma: Gynecologic Oncology Group Studies Bolla, M., et al, eds, Endometrial Cancers, 5th Cancer Research Workshop, pp. 256-266, 1986, Karger, Basel | 1986 |
| Thigpen, T., Blessing, J., DiSaia, P., and Ihrlich, C Medroxyprogesterone Acetate in Advanced or Recurrent Endometrial Carcinoma: Results of Therapy and Correlation with Estrogen and Progesterone Receptor Levels. The Gynecologic Oncology Group Experience Baubieu, E., Iacobilli, S., and McGuire, W., eds, Endocrinology and Malignancy, pp. 446-454, Parthenon Publishing Group, Park Ridge New Jersey, 1986 | 1986 |
| Balducci, L., Wallace, C., Khansur, T., Vance, R., Thigpen, T., and Hardy, C Nutrition, Cancer and Aging: An Annotated Review Journal of American Geriatrics Society 34:127-136, 1986 | 1986 |
| Thigpen, T., and Blessing, J. A Current Therapy of Ovarian Carcinoma: An Overview Seminars in Oncology 2:47-52, 1985 | 1985 |
| Thigpen, T Management of Ovarian Cancer Proceedings of the Second International Symposium on Recent Advances in Medical Oncology: Mexico City, Mexico, Bristol Myers, New York, 1985 | 1985 |
| Thigpen, T Management of Patients with Ovarian Carcinoma In Advances in Oncology, vol. 1, no. 1, CPC Communications, New York, 1985 | 1985 |
| Thigpen, T Management of Ovarian Carcinoma Clinical Cancer Briefs 6, No. 2:12-21, 1984 | 1984 |
| Balducci, L., Chapman, J., Gong, J., Dreling, B., Steinberg, M. Vance, R., Thigpen, T., Morrison, F., and Barnes, T Multiple Myeloma: A Reappraisal from a General Hospital J. Exp. Clin. Cancer Res. 3:425-432, 1984 | 1984 |
| Thigpen, T., Vance, R., Balducci, L., and Khansur, T New Drugs and Experimental Approaches in Ovarian Carcinoma Seminars in Oncology 11:314-326, 1984 | 1984 |
| Balducci, L., Halbrook, J., Chapman, S., Vance, R., Thigpen, T., and Morrison, F Acute Leukemia and Infections: Perspectives from a General Hospital American Journal of Hematology 5:57-63, 1983 | 1983 |
| Thigpen, T., Blessing, J., Homesley, H., and Adcock, L Phase II Trial of Piperazinedione (NSC 135758) in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study American Journal of Clinical Oncology 6:423-426, 1983 | 1983 |
| Thigpen, T Chemotherapy in Ovarian and Cervical Carcinoma Bristol lab, 1982 Bristol lab, 1982 | 1982 |
| Kapp, J., Vance, R., Routh, A., and Thigpen, T Neurosurgical Complications of Breast Cancer J. Miss. State Med. Assoc. 23:309-313, 1982 | 1982 |
| Arseneau, J., and Thigpen, T The New Quack-Pseudoscience, Public Relations, and Politics: 1980's Style J. Miss. State Med. Assoc. 22:202-207, 1981 | 1981 |
| Thigpen, J. T., and Clay, J. C The Rationale for Current Approaches to Therapy of Malignant Neoplasia Alabama Journal of Medical Sciences 13:252-259, 1976 | 1976 |
| Morrison, F. S., Dreiling, B. J., Thigpen, J. T., and Stubblefield, G. C Self-Assessment of Current Knowledge in Hematology Part 2: Literature Review, Medical Examination Publishing Company, Flushing, New York, 1975 | 1975 |
| Thigpen JT, Alberts D, Birrerr M, Copeland L, Coleman RL, Markman M, Bast RC Jr, Eisenhauer EL, Fleming G, Fracasso PM, Gershenson DM, Herzog T, Monk BJ, Ozols RF, Rustin G, Shrader M, and Ranganathan A Current Challenges and Future Directions in the Management of Ovarian Cancer: Proceedings of the First Global Workshop on Ovarian Cancer In press in J Clin Oncol | |
| Boronow, R. C., and Thigpen, J. T Management of Recurrent Endometrial Cancer Dial Access Cancer Information, Southern Medical Association, and M. D. Anderson Hospital and Tumor Institute | |
| Thigpen, T., Vance, R., Khansur, T., and Malamud, F The Role of Paclitaxel in the Management of Carcinoma of the Cervix Semin. Oncol. 24 (Suppl. 2): S241-S246 | |
Abstracts |
| Thigpen T, duBois A, McAlpine J, DiSala P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Paveda A, Rubinstein L, Bacon M, Kitchener H and Stuart GC First-Line Therapy in Ovarian Cancer Trials. Int J Gynecol Cancer 21: 756-62 | 2011 |
| Thigpen T, DuBois A, Markman M, Swart AM, Reed N, Hoskins W, Kristensen G, Quinn M, Fujiwara K, Mannel R, DiSaia P, Pfisterer J on behalf of the Gynecologic Cancer Intergroup The Fourth Ovarian Carcinoma Consensus Conference of the Gynecologic Cancer Intergroup: Clinical Trials Involving Patients with Newly Diagnosed Disease Int J Gynecol Cancer 21: 419-23 | 2011 |
| Moore KN, Tian C, McMeekin S, Thigpen JTY, and Randall ME gression-Free Interval Following First-Line Chemotherapy Is Asscoiated with Survival Following Second-Line Chemotherapy in Advanced and Recurrent Endometrial Cancer: a Gynecologic Oncology Group Ancillary Data Analysis Gynecologic Oncology 112: S35, 2009 | 2009 |
| Farley JH, Sill M, Walker JL, Schilder RJ, Thigpen JT, Coleman RL, and Miller BE Phase II Evaluation of Cisplatin plus Cetuximab in the Treatment of Recurrent and Persistent Cancers of the Cervix: a Limited Access Phase II Study of the Gynecologic Oncology Group Proc ASCO 27: 282s, 2009 | 2009 |
| Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Thigpen JT, Fleming GF, Gallion HH, and Maxwell GL Chemotherapy Intensity and Toxicity among Black and White Women with Advanced or Recurrent Endometrial Cancer: Experience from Gynecologic Oncology Group Clinical Trials Gynecologic Oncology 108: S19, 2008 | 2008 |
| Modesitt S, Tian C, Kryscio R, Thigpen T, Randall M, Gallion H, and Fleming G Impact of Body Mass Index on Treatment Outcomes in Advanced or Recurrent Endometrial Cancer Patients Receiving Doxorubicin/Cisplatin Chemotherapy: a Gynecologic Oncology Group Study Gynecol Oncol 101: S42, 2006 | 2006 |
| Rose, P, Bundy, Thigpen, T Significant Preliminary Results of a Phase III Randomized Study of Concomitant Chemoradiation with Hydroxyurea vs Hydroxyurea, 5-FU Infusion, and Bolus Cisplatin vs Weekly Cisplatin in Advanced Cervix Cancer, a GOG Study Gynecol Oncol 68:104, 1998 | 1998 |
| Thigpen, T., Blessing, J., Homesley, H., Reid, G. and Olt, G Cisplatin as Salvage Therapy in Ovarian Carcinoma Treatment Initially with Single-Agent Paclitaxel: A Gynecologic Oncology Group Study Proc. ASCO 15:286, 1996 | 1996 |
| Thigpen, J. T Management of Ovarian Carcinoma: The Role of Paclitaxel in Front-Line and Salvage Therapy Cancer Investigation 14 (Suppl. 1): 12-13, 1996 | 1996 |
| Thigpen, T., Blessing, J., Lincoln, S., Homesley, H., and Sutton, G Phase II Trial of Cisplatin in Mixed Mesodermal Sarcomas of the Ovary Gynecologic Oncology: 141, 1996 | 1996 |
| Thigpen, T., Blessing, J., Homesley, H., Malfetano, J., DiSaia, P., and Yordan, E Phase III Trial of Doxorubicin plus or minus Cisplatin in Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study Proc. ASCO 12:261, 1993 | 1993 |
| Thigpen, T., Blessing, J., Ball, H., Hummel, S., and Barrett, R Phase II Trial of Taxol as Second-Line Therapy for Ovarian Carcinoma: A Gynecologic Oncology Group Study Proc. ASCO 9:155, 1990 | 1990 |
| Williams, Stephen D., Blessing, John a., Slayton, Robert, Homesley, Howard, and Thigpen, James Tate Ovarian Germ Cell Tumors: Adjuvant Trials of the Gynecologic oncology Group SGO, 1989 | 1989 |
| Thigpen, T., Blessing, J., DiSaia, P., Shingleton, H., and Fowler, W Cisplatin in the Management of Patients with Advanced or Recurrent Squamous Carcinoma of the Cervix: Effects of Prolonged Infusion Proc. ASCO 5:116, 1986 | 1986 |
| Baldwin, L., Thigpen, T., and Hardy, C Hemopoietic Effects of Trazofurin (TZ) in Normal and Tumor Bearing Animals Proc. AARC 27:307, 1986 | 1986 |
| Thigpen, t., Blessing, J., DiSaia, P., and Ehrlich, C Oral Medroxyprogesterone Acetate in Advanced Endometrial Carcinoma Anticancer Research 6:3555, 1986 | 1986 |
| Thigpen, T., Blessing, J., DiSaia, P., and Ehrlich, C A Randomized Comparison of Adriamycin with or without Cyclophosphamide in the Treatment of Advanced or Recurrent Endometrial Carcinoma Proc. ASCO 4:115, 1985 | 1985 |
| Thigpen, T., Blessing, J., DiSaia, P., and Ehrlich, C Treatment of Advanced or Recurrent Endometrial Carcinoma with Medroxyprogesterone Acetate Gynecologic Oncology 20:250, 1985 | 1985 |
| Balducci, L., Gong, J., Dreiling, B., Vance, R., Chapman, S., Thigpen, T., and Morrison, F Multiple Myeloma: A Reappraisal from a General Hospital Clinical Research 31:854A, 1983 | 1983 |
| Thigpen, T., Shingleton, H., Homesley, H., and Blessing, J Phase II Trial of Cis-Diamminedichloroplatinum (DDP) in Treatment of Advanced or Recurrent Mixed Mesodermal Sarcoma of the Uterus Proc. ASCO 1:110, 1982 | 1982 |
| Balducci, L., Chapman, S., Halbrook J., Thigpen, T., Vance, R., and Morrison, F Causes of Death in Acute Leukemia: Perspectives from a General Hospital Proc. ASCO 22:423, 1981 | 1981 |
| Jobson, V., Muss, H., Thigpen, T., and Homesley, H Chemotherapy of Advanced Carcinoma of the Cervix with Cyclophosphamide and Cisplatin Proc. ASCO 22:475, 1981 | 1981 |
| Thigpen, T., Blessing, J., DiSaia, P., and LaGasse, L Phase II Trial of Cis-Diamminedichloroplatinum in the Management of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study Proc. ASCO 22:469, 1981 | 1981 |
| Thigpen, T., Blessing, J., DiSaia, P., and LaGasse, L Phase II Trial of Cis-Diamminedichloroplatinum in the Management of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study Proc. ASCO 22:469, 1981 | 1981 |
| Balducci, L., Halbrook, J., Chapman, S., Vance, R., Thigpen, T., and Morrison, F Infections in Acute Leukemia: Perspectives from a General Hospital Clinical Research 28:836A, 1980 | 1980 |
| Thigpen, T., Ehrlich, C., and Blessing, J Phase II Trial of Maytansine in Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Cervix Proc. ASCO 21:424, 1980 | 1980 |
| Thigpen, T., Shingleton, H., and Homesley, H Phase II Trial of Cisplatinum as First or Second - Line Treatment for Advanced Squamous Cell Carcinoma of the Cervix Proc. ASCO 10:388, 1979 | 1979 |
| Thigpen, T., LaGasse, L., and Bundy, B Phase II Trial of Cisplatinum in Treatment of Advanced Ovarian Adenocarcinoma Proc. AACR 20:84, 1979 | 1979 |
| LaGasse, L., Thigpen, T., and Morrison, F Phase II Trial of Piperazinedione in Treatment of Advanced Endometrial Carcinoma, Uterine Sarcoma, and Vulvar Carcinoma Proc. ASCO 20:388, 1979 | 1979 |
| Lee, S. H. Thigpen, J. T., and Langford, H. G Interference with c-AMP Action as the Cause of Hypomagnesemic Hypocalcemia Clin. Res. 26:24A, 1978 | 1978 |
| Balducci, L., Newcomb, M., Thigpen, J. T., and Morrison, F. S Leukemia in Pregnancy: Successful Delivery after Cytarabine and Adriamycin Clin. Res. 26:34A, 1978 | 1978 |
| Thigpen, T., and Shingleton, H Phase II Trial of Cisplatinum in Treatment of Advanced Squamous Cell Carcinoma of the Cervix Proc. ASCO 19:332, 1978 | 1978 |
| Delgado, G., Thigpen, T., Dolan, T., and Morrison, F Phase II Trial of Piperazinedione in Treatment of Advanced Ovarian Adenocarcinoma Pro. ASCO 19:332, 1978 | 1978 |
| Thigpen, T., Morrison, F., and Baker, L Phase II Evaluation of Diahydrogalactitol (DAG) in Treatment of Advanced Sarcoma and Malignant Melanoma Proc. AACR-ASCO 18:240, 1977 | 1977 |
| Thigpen, T., Torres, J., Buchsbaum, H., and Blessing, J Phase II Trial of Adriamycin in Treatment of Endometrial Adenocarcinoma Proc. AACR-ASCO 18:352, 1977 | 1977 |
| Livingston, R. B., Thigpen, J. T., and Hart, J BACON-NAC in Squamous Cell Carcinoma of the Lung Proceedings ASCO-AACR 17:273, 1976 | 1976 |
| Morrison, F. S., Stubblefield, G. C., Jr., and Thigpen, J. T Acute Leukemia During Pregnancy. Read before the Southwest Section American Association for Cancer Research, November, 1974 | 1974 |
| Morrison, F. S., and Thigpen, J. T Diagnostic Considerations in the Leukemic Patient with Central Nervous System Disease. Read before the Southwest Section American Association for Cancer Research, November, 1974 | 1974 |
| Steinberg M. H., Adams, J. G., Thigpen, J. T., Morrison, F. S., and Dreiling, B. J Hemoglobin Hope (2 B2136 gly-asp) - S Disease Clinical Research 22:408A, 1974 | 1974 |
| Moore, D. H., Montana, G. S., Bundy, B. N., Bell, J., Thigpen, J. T. and Olt, G Preoperative Chemoradiation for Advanced Vulvar Cancer: A Phase II Study of the Gynecologic Oncology Group Gynecologic Oncology | |
Book Chapter |
| Thigpen T and Blessing J The GOG Scientific Process: a Unique Approach to Cooperative Clinical Trials DiSaia P, ed, The Gynecologic Oncology Group: Report of 35 Years of Excellence in Clinical Research, Gynecologic Oncology Group Philadelphia, 2006, pp 7-11 | 2006 |
| Thigpen, J. T Cancers of the Ovary and Fallopian tubes Abeloff, M., Armitage, J., Lichter, A., Niederhuber J., eds., Clinical Oncology, Third Edition, Churchill-Livingstone, NY, 2004 | 2004 |
| Thigpen T Current Controversies in Ovarian Cancer: Maintenance Chemotherapy as Standard Care ASCO Educational Book 2004, pp. 281-283 | 2004 |
| Thigpen, J.T Evidence-Based Management of recurrent Ovarian Cancer Thigpen, J.T., ed, Management of Advanced Ovarian cancer in 2004: Progress and Promise, American Academy of CME, 2004, pp 33-48 | 2004 |
| Thigpen T Gynecologic Cancers in the Elderly Balducci L, Lyman G, Ershler W and Extermann M, eds, Comprehensive Geriatric Oncology, Second Edition, 2004, Martin Dunitz, New York | 2004 |
| Thigpen T Gynecologic Cancers ASCO Curriculum: Cancer Care in the Older Population, 2002 | 2002 |
| Bloss, J. and Thigpen, T Chemotherapy of Gynecologic Cancers Perry, M., ed, The Chemotherapy Source Book, Third Edition, Lippincott Williams and Wilkins, Philadelphia, 2001, pp. 732-759 | 2001 |
| Barakat R., Greven K., Markman M., Thigpen T Endometrial Cancer Cancer Management: A Multidisciplinary Approach 2001, PRR, New York, 2001, pp 391-409 | 2001 |
| Thigpen T., Herrin V Recent developments in the treatment of recurrent ovarian carcinoma Rubin S and Sutton G, eds, Ovarian Cancer, Second Edition, Lippincott, Williams and Wilkins, Philadelphia, 2001, pp 301-314 | 2001 |
| Thigpen, J. T Cancers of the Ovary and Fallopian tubes Abeloff, M., Armitage, J., Lichter, A., Niederhuber J., eds., Clinical Oncology, Second Edition, Churchill-Livingstone, NY, 2000, pp. 2016-2040 | 2000 |
| Eifel, P., Berek, J., and Thigpen, T Cancers of the Vulva, Vagina, and Cervix Devita, V. T. Jr., Hellman S. and Rosenberg, S., eds., Cancer: Principles and Practice of Oncology, Sixth Edition, Lippincott, Philadelphia 2000 | 2000 |
| Barakat R., Greven K., Thigpen T Endometrial cancer Pazdur R, Coia L, Wagman L and Hoskins W, eds: Cancer Management: A Multidisciplinary Approach, Fourth Edition, PRR, New York, 2000, pp. 269-286 | 2000 |
| Cancer of the Uterine Cervix Hoskins, W., Perez, C., and Young, R. C., eds., Principles and Practices of Gynecologic Oncology, Second Edition, J. B. Lippincott, Philadelphia, 2000 Stehman, F., Perez, C., and Thigpen, T. “Cancer of the Uterine Cervix | 2000 |
| Thigpen, T Cancers of the Female Genitourinary Tract Gotto A, ed, Current Practice of Medicine: Oncology, Current Medicine, Philadelphia, 1999, pp. 1259-1266 | 1999 |
| Thigpen T Chemotherapy in celomic epithelial carcinoma of the ovary: state of the art Current Research Therapy and Control, Overseas Publishers Association, Amsterdam, 1999, pp 1-11 | 1999 |
| Herrin V., Thigpen T Germ cell tumors of the ovary Raghavan D, Brecher M, Johnson D., Meropol N., Mopots P.,Thigpen T, eds, Textbook of Uncommon Cancer, Second Edition, John Wiley & Sons, New York, 1999, pp. 671-680 | 1999 |
| Thigpen T Gynecologic cancer Current Oncology Reports 1: 39-84, 1999 | 1999 |
| Garcia A., Thigpen T Tumors of the vulva and vagina Raghavan D, Brecher M, Johnson D., Meropol N., Mopots P., Thigpen T, eds: Textbook of Uncommon Cancer, Second Edition, John Wiley & Sons, New York, 1999, pp. 701-712 | 1999 |
| Thigpen, T Cancers of the Female Genitourinary Tract Bone, R, ed. Current Practice of Medicine, Second Edition, Lippincott, Philadelphia, 1998 | 1998 |
| Munkarah, A., Thigpen, T Management of Adverse Effects of Chemotherapy Deppu, G., ed. Chemotherapy of Gynecologic Cancer, Third Edition, Wilg-Liss, New York, 1998 | 1998 |
| Thigpen, T. and Garcia, A Principles of Chemotherapy Morrow, C. P., ed., Synopsis of Gynecologic Oncology, Fifth Edition, Churchill-Livingston, New York, 1998 | 1998 |
| Stehman, F., Perez, C., and Thigpen, T Cancer of the Uterine Cervix Hoskins, W., Perez, C., and Young, R. C., eds., Principles and Practices of Gynecologic Oncology, Second Edition, J. B. Lippincott, Philadelphia, 1997, pp. 785-858 | 1997 |
| Eifel, P., Berek, J., Thigpen, T Cancers of the Vulva, Vagina, and Cervix Devita, V. T. Jr., Hellman S. and Rosenberg, S., eds., Cancer: Principles and Practice of Oncology, Fifth Edition, Lippincott, Philadelphia 1997, pp. 1433-1477 | 1997 |
| Thigpen, T Cervical and Endometrial Cancer Kassirer, J. and Greene, H., eds. Current Therapy in Adult Medicine, Fourth Edition, Mosby, Philadelphia, 1997, pp. 163-170 | 1997 |
| Thigpen, T Chemotherapy of Gynecologic Cancer Perry, M., ed. The Chemotherapy Source book, Second Edition, Williams and Willins, Baltimore, 1997, pp. 1253-1288 | 1997 |
| Curtin, J. P., Silverberg, S. G., Thigpen, J. T., and Spanos, W. J Corpus: Merenchymal Tumors Hoskins W. J., Perez, C., and Young, R. C., eds., Principles and Practice of Gynecologic Oncology, Second Edition, J. B. Lippincott, Philadelphia, 1997, pp. 897-918 | 1997 |
| Thigpen, T Gynecologic Cancers in the Elderly Balducci, L., Ershler, W., and Lyman, G., eds., Comprehensive Geriatric Oncology, Second Edition, Harwood, London, 1997, pp. 723-734 | 1997 |
| Cohen, C., Thomas, G. and Thigpen, T Gynecologic Sarcomas Holland, J. F., and Frei, T., eds., Cancer Medicine, 4th Edition, Lea and Febiger, New York, 1997 | 1997 |
| Vasey, P., Kaye, S., Thigpen, T Importance of Dose Intensity in Ovarian Cancer Gershenson, D. and McGuire, W. P., eds., Ovarian Cancer: Controversies in Management, Churchill-Livingston, New York, 1997, pp. 139-168 | 1997 |
| Thigpen, T Chemotherapy of Advanced or Recurrent Cervical Cancer Rubin, S., and Hoskins, W., eds., Cervical Cancer and Preinvasive Neoplasia, Lippincott-Raven, Philadelphia, 1996, pp. 331-342 | 1996 |
| Greco, F. A., Evans, W. K., Holmes, F. A., Longo, D. L., MacDonald, J.S., Thigpen, J. T Handbook of Commonly Used Chemotherapy Regimens Precept Press, Chicago, 1996 | 1996 |
| Thigpen, T The Role of chemotherapy in Gynecologic Cancer Rubin S., ed., SGO Handbook: Chemotherapy of Gynecological Cancers, Lippincott-Raven, Philadelphia, 1996, pp. 91-112 | 1996 |
| Thigpen, J. T Cancers of the Ovary and Fallopian tubes Armitage, J., Lichter, A., Niederhuber J., eds., Clinical Oncology, pp. 1595-1616. Churchill-Livingstone, NY, 1995 | 1995 |
| Thigpen, T Cervical and Endometrial Cancer Carbone, P., and Brain, M. Current Therapy in Hematology-Oncology. Mosby, St. Louis, 1995, pp. 458-465 | 1995 |
| Thigpen, T Gynecologic Cancers McDonald, Jr., Haller, D., and Mayer, R. J., eds. Manual of Oncologic Therapeutics, Third Edition, Lippincott, Philadelphia, 1995, pp. 212-225 | 1995 |
| Thigpen, T Cancers of the Female Genitourinary Tract Boone, R. C., Ed, Current Practice of Medicine: Oncology, Current Medicine, Philadelphia, 1994, pp. XII. 6. 1-7 | 1994 |
| Thigpen, T Chemotherapy for Cervical Carcinoma Hoskins, W., Perez, C., and Young, R., eds, Principles and Practices of Gynecologic Oncology, J. B. Lippincott, Philadelphia, pp. 636-641, 1992 | 1992 |
| Thigpen, J. T Chemotherapy in the Management of Cancers of the Female Genital Tact Perry, M. D., ed, The Chemotherapy Source Book, pp. 1039-1067, Williams and Wilkins, Baltimore, 1992 | 1992 |
| Thigpen, J. T Chemotherapy in Uterine Sarcomas Hoskins, W., Perry, C., and Young, R. eds., Principles and Practice of Gynecologic Oncology, J. B. Lippincott, Philadelphia, pp. 709-712, 1992 | 1992 |
| Thigpen, T Systemic Therapy in the Management of Cancer of the Vulva Knapstein, P. G., DiRe, F., DiSaia, P., Haller, U., and Scoin, V. U., eds Malignancies of the Vulva, pp. 153-158, Thieme, New York, 1991 | 1991 |
| Thigpen, T The Management of Adverse Effects of Chemotherapy Deppe, G., ed. Chemotherapy in Gynecologic Cancer, pp. 41-61, Wiley-Liss, New York, 1990 | 1990 |
| Thigpen, T Single Agents in Endometrial Carcinoma Alberts, D. and Surwit, E. eds. Endometrial Carcinoma, pp. 93-106, Martinus Nijhoff, Boston, 1989 | 1989 |
| Thigpen, T., and Bundy, B Adjuvant Therapy for Gynecologic Cancer Salmon, S., ed., Adjuvant Therapy V, 1987, Grune and Stratton | 1987 |
| Thigpen, T Chemotherapy in Gynecologic Cancer Morrow, P., and Townsend, D., eds. Synopsis of Gynecologic Oncology, Third Edition, Wiley, Philadelphia, 1987 | 1987 |
| Thigpen, T Single Agent Chemotherapy for Carcinoma of the Cervix Surwit, E., and Alberts, D. eds, Cervix Cancer, Martinus Nijhoff, Boston, 1986 | 1986 |
| Thigpen, T Single Agent therapy in the Management of Ovarian Carcinoma In Alberts, D., and Surwit, E., eds, Ovarian Cancer, pp. 115-146, Martinas Nijhoff, Boston, 1985 | 1985 |
| Thigpen, T Approaches to the Evaluation and Management of Endometrial Carcinoma Forastiere, Arlene, ed., Gynecologic Cancer, Churchill Livingston inc., New York, 1984 | 1984 |
| Thigpen, T Chemotherapy in Gynecologic Cancer In Press in Rivlin, M., ed., Manual of Obstetrics and Gynecology, pp. 419-424, 1982, Little, Brown Company, Boston | 1982 |
| Thigpen, T. Chemotherapy for Ovarian Carcinoma Ballon, S., ed., New Directions in Gynecologic Oncology, pp. 272-293, G. K. Hall, Boston, 1981 | 1981 |
| Thigpen, J. T Viral Infections Brunson, J. G., and Gall, E. A., ed. Concepts of Disease: A Textbook of Human Pathology. Pp. 644-672, MacMillan Company, New York, 1971 | 1971 |
| Thigpen, J. T Chemotherapy in the Management of Celomic Epithelial Carcinoma of the Ovary Hoskins, W. J., and Markman, M., eds., Cancer of the Ovary, Rowen Press, New York, pp. 277-286 | |
Book |
| Arceci RJ, Bauer TL II, Gordon MS, Lawton CA, and Thigpen JT Year Book of Oncology 2010 Elsevier Mosby, Philadelphia, 2010 | 2010 |
| Barker JA, Berney SM, Garrick R, Gersh BJ, Khardori NM, Leroith D, Talley NJ, and Thigpen JT Year Book of Medicine 2009 Elsevier Mosby, Philadelphia, 2009 | 2009 |
| Thigpen JT, Arceci RJ, Bauer TL II, Byhardt R, Gordon MS, and Lawton CA Year Book of Oncology 2009 Elsevier Mosby, Philadelphia, 2009 | 2009 |
| Loehrer PJ, Arceci RJ, Glatstein E, Gordon MS, Hanna NH and Thigpen JT Year Book of Oncology 2008 Elsevier Mosby, Philadelphia, 2008 | 2008 |
| Loehrer PJ, Arceci RJ, Glatstein E, Gordon MS, Morrow M, Schiller JH and Thigpen JT Year Book of Oncology 2007 Mosby, Philadelphia, 2007 | 2007 |
| Loehrer PJ, Arceci RJ, Glatstein E, Gordon MS, Morrow M, Schiller JH and Thigpen JT Year Book of Oncology 2006 Mosby, Philadelphia, 2006 | 2006 |
| Loehrer PJ, Arceci RJ, Glatstein E, Gordon MS, Morrow M, Schiller JH and Thigpen JT Year Book of Oncology 2005 Mosby, Philadelphia, 2005 | 2005 |
| Loehrer, P.J., Arceci, R.J.,Glatstein E., Gordon, M.S., Morrow, M., Schiller, J.H., Thigpen, J.T Year Book of Oncology 2004 Mosby, Philadelphia, 2004 | 2004 |
| Thigpen JT Gynecologic Cancers Section Editor, Current Oncology Reports 6: 447-485, 2003 | 2003 |
| Loehrer, P.J., Arceci, R.J., Glatstein, E., Gordon, M.S., Johnson, D.H., Morrow, M., Thigpen, J.T Year Book of Oncology 2003 Mosby, Philadelphia, 2003 | 2003 |
| Thigpen JT Gynecologic Cancers Section Editor, Current Oncology Reports 2: 145-183, 2002 | 2002 |
| Loehrer, P., Eisenberg, B., Glatstein, E., Gordon, M., Johnson, D., Pratt, C. and Thigpen Yearbook of Oncology 2002 Mosby, St. Louis, 2002 | 2002 |
| Loehrer, P., Eisenberg, B., Glatstein, E., Gordon, M., Johnson, D., Pratt, C. and Thigpen, T Yearbook of Oncology 2001 Mosby, St. Louis, 2001 | 2001 |
| Bajorin D., Benjamin R., Hagemeister F., Lippman S., Moskowitz C., Schwartz J., Thigpen T Ifosfamide and Mesna: Experience with Outpatient and Inpatient Administration Bristol-Myers Squibb, Princeton, NJ, 2000 | 2000 |
| Thigpen T., Markman M., McGuire W.P., Ozols R Recent Developments in First-Line Therapy for Patients with Advanced Ovarian Cancer Gynecologic Oncology Group, Philadelphia, 2000 | 2000 |
| Loehrer, P., Eisenberg, B., Glatstein, E., Gordon, M., Johnson, D., Pratt, C. and Thigpen, T Yearbook of Oncology 2000 Mosby, St. Louis, 2000 | 2000 |
| Thigpen JT Gynecologic Cancers Section Editor, Current Oncology Reports 1: 41-84, 1999 | 1999 |
| Raghavan D., Brecher M., Johnson D., Meropol N., Mopots P., Thigpen T Uncommon Cancer Second Edition, John Wiley & Sons, New York, 1999 | 1999 |
| Thigpen, T. and Markman, M Carboplatin versus Cisplatin in the Treatment of Advanced Ovarian Cancer BMSO, Princeton, NJU, 1997 | 1997 |
| Thigpen, J. T., and Hoskins, W. J Cancer of the Ovary Bristol-Myers Squibb, Princeton, N. N.J., 1992 | 1992 |
| Brady, L., Lewis, G., Thigpen, T., and Yerger, T Ovarian Tumors Pergammon Press, New York, 1984 | 1984 |
Editorial Commentary |
| Thigpen JT Advanced or Recurrent Carcinoma of the Uterine Cervix: To Treat or Not To Treat and with What Clin Ovarian Cancer 1: 89-90, 2008 | 2008 |
| Thigpen JT Intraperitoneal Chemotherapy: the Standard or an Option Clin Ovarian Cancer 1: 8-9, 2008 | 2008 |
| Thigpen T Maybe More Is Better J Clin Oncol 21: 2454-2456, 2003 | 2003 |
| Thigpen, T Review of: Is There a Role for Intraperitoneal Chemotherapy in the Management of Ovarian Cancer Oncology 15: 104-105, 2001 | 2001 |
| Thigpen T If and when? The role of chemotherapy in locally advanced carcinoma of the cervix Ann Oncol 9: 933-936, 1998 | 1998 |
| Thigpen, T Dose-Intensity in Ovarian Carcinoma: Hold, Enough J. Clin. Oncol. 15: 1291-1293, 1997 | 1997 |
| Thigpen, T High-Dose Chemotherapy with Autologus Bone Marrow Support in Ovarian Carcinoma: The Bottom Line, More or Less Gynecol Oncol. 57: 275-277, 1995 | 1995 |
| Thigpen, J. T Ifosfamide Induced Central Nervous System Toxicity Gynecol. Oncol. 42:191-192, 1991 | 1991 |
| Thigpen, T Discussion Gynecology Oncology, 31:246-247, 1988 | 1988 |
| Thigpen, T Discussion Gynecologic Oncology, 27:261-263, 1987 | 1987 |
Letter to the Editor |
| Rustin G, Quinn M, Thigpen T, DuBois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J Correspondence Re: New Guidelines To Evaluate the Response to Treatment in Solid Tumors J Natl Cancer Instit 96: 487-488, 2004 | 2004 |
| Ozols, R.F., Markman, M., Thigpen, J.T ICON3 and Chemotherapy for Ovarian Cancer Lancet 360: 2086-2087, 2002 | 2002 |
